Iogenetics, LLC

9 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Nov 2031

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

No maintenance fee falls due on this company's record before Nov 14, 2027.

Recent changes

1 of the patents on this record was granted since Aug 16, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 9 of 9

Patent	Title	Status	Expires	Confidence
US 10,706,955	Bioinformatic Processes for Determination of Peptide Binding In force Term ends Nov 25, 2031 · High confidence	In force	Term ends Nov 25, 2031	High confidence
US 11,640,847	Bioinformatic Processes for Determination of Peptide Binding In force Term ends Nov 25, 2031 · Low confidence	In force	Term ends Nov 25, 2031	Low confidence
US 12,374,421	Bioinformatic processes for determination of peptide binding In force Term ends Aug 17, 2034 · From the USPTO record	In force	Term ends Aug 17, 2034	From the USPTO record
US 10,799,582	Immunoglobulin Polypeptide Fractions from Products of Domestic Animals In force Term ends Jun 2, 2036 · High confidence	In force	Term ends Jun 2, 2036	High confidence
US 12,752,004	Enhancement of immune response with oral immunoglobulin polypeptides In force Term ends Jun 2, 2036 · High confidence	In force	Term ends Jun 2, 2036	High confidence
US 11,069,427	Mathematical Processes for Determination of Peptidase Cleavage In force Term ends Jan 13, 2037 · High confidence	In force	Term ends Jan 13, 2037	High confidence
US 11,434,259	Modified Zika virus NS1 protein with reduced cross-reactive immunogenicity In force Term ends Jan 25, 2037 · From the USPTO record	In force	Term ends Jan 25, 2037	From the USPTO record
US 10,755,801	Identifying Peptides Having T-Cell-Exposed Motifs with Known Frequency of Occurrence in a Reference Database In force Term ends Aug 12, 2037 · High confidence	In force	Term ends Aug 12, 2037	High confidence
US 12,569,546	Neoantigen Immunotherapies In force Term ends Oct 28, 2042 · High confidence	In force	Term ends Oct 28, 2042	High confidence

Also on record, not counted in the 9: 1 lapsed for an unpaid fee · 3 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

9 pending · 4 abandoned · 9 no status recorded

List them